Parasitological, Histopathological and Regulatory Micro RNA Assessment in Chronic Murine Toxoplasmosis Treated with Bee Venom

This research aimed to compare the potential anti-toxoplasma impact of Bee venom (B.v.) against the commercial drug spiramycin (SPI) on chronic toxoplasmosis parasitologically. A histopathological evaluation of the me49 infection was performed on the brain, liver, and lungs. Host regulatory microRNAs miR-712-3p and miR-146b-5p were measured before and after the tested drugs were administered in the sera of Swiss albino mice. Group A served as the control group, subdivided into 4 subgroups, while Group B was further separated into four me49 infected subgroups. When compared to the positive control, the combination of B.v. and SPI had the best outcomes, with a statistically significant 94.1% reduction in brain cyst count. Me49 infection resulted in a significant rise in the level of miR-712-3p expression in rats’ serum. Furthermore, after infection, there was a 50-fold rise in miR-146b-5p in host sera. Following the tested medications' treatment of the diseased mice, these levels dropped.